Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).

Cardiovascular drugs and therapy - 1 Jun 2020

Judge Daniel P, Kristen Arnt V, Grogan Martha, Maurer Mathew S, Falk Rodney H, Hanna Mazen, Gillmore Julian, Garg Pushkal, Vaishnaw Akshay K, Harrop Jamie, Powell Christine, Karsten Verena, Zhang Xiaoping, Sweetser Marianne T, Vest John, Hawkins Philip N

Abstract excerpt

PURPOSE: The Phase 3 ENDEAVOUR study evaluated revusiran, an investigational RNA interference therapeutic targeting hepatic transthyretin (TTR) production, for treating cardiomyopathy caused by hereditary transthyretin-mediated (hATTR) amyloidosis. METHODS: Patients with hATTR amyloidosis with cardiomyopathy were randomized 2:1 to receive subcutaneous daily revusiran 500 mg (n = 140) or placebo (n = 66) for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid Neuropathies, Familial
Share to Canada

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cardiomyopathies

Share to Cause of Death

Share to Exercise Tolerance

Share to Prealbumin

Share to Recovery of Function

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 32062791
DOI: 10.1007/s10557-019-06919-4
PMCID: PMC7242280

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).PMID 32062791Read ↗

Transthyretin Amyloid Cardiomyopathy Treatment: An Updated ReviewSemantic proximity Read ↗

Transthyretin Amyloid Cardiomyopathy–2025 Update: Current Diagnostic Approaches and Emerging Therapeutic OptionsSemantic proximity Read ↗

Transthyretin cardiac amyloidoses in older North Americans.Semantic proximity Read ↗

Emerging Pharmacological Strategies for Cardiac Amyloidosis: A Qualitative Analysis of Interventional Clinical Trials Registered on ClinicalTrials.govSemantic proximity Read ↗

A phase 3 clinical trial with ISIS-TTRRx, a 2nd-generation antisense oligonucleotide targeting transthyretin (TTR), for the treatment of TTR amyloid cardiomyopathySemantic proximity Read ↗

The transthyretin amyloidoses: advances in therapySemantic proximity Read ↗

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studySemantic proximity Read ↗

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort studySemantic proximity Read ↗

A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.Semantic proximity Read ↗

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trialsSemantic proximity Read ↗

Disease-Modifying Treatments for Transthyretin Amyloidosis.Semantic proximity Read ↗

Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.